RECEPTOR ACTIVATOR OF NF-KB (RANK) EXPRESSION ASSOCIATES WITH BONE METASTASIS IN BREAST CARCINOMAS

被引：0
|
作者：
Santini, D.
Vincenzi, B.
Russo, A. [1 ]
Ortega, C. [2 ]
Porta, C. [6 ]
Galluzzo, S.
La Verde, N. [3 ]
Caroti, C. [4 ]
Addeo, R. [5 ]
Tonini, G.
机构：
[1] Univ Palermo, Palermo, Italy
[2] IRCC, Univ Div Med Oncol & Haematol, Turin, Italy
[3] Fatebenefratelli Oftalm Hosp, Milan, Italy
[4] EO Ospedali Galliera, Genoa, Italy
[5] S Giovanni Dio Hosp, Naples, Italy
[6] San Matteo Univ Hosp, IRCCS, Pavia, Italy
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
101P
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [41] Differential expression of active phosphorylated NF-kB/Rela in normal and psoriatic skin and down-regulation of NF-kB by etanercept
    Lizzul, P
    Aphale, A
    Malaviya, R
    Gottlieb, AB
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P203 - P203
  • [42] Differential expression of phosphorylated NF-kB/RelA in normal and psoriatic epidermis and downregulation of NF-kB in response to treatment with etanercept.
    Lizzul, PF
    Aphale, A
    Malaviya, R
    Sun, Y
    Masud, S
    Donbrovskiy, V
    Gottlieb, AB
    CLINICAL IMMUNOLOGY, 2005, 115 : S38 - S38
  • [43] Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANKL) serum levels in patients on chronic hemodialysis.
    Gonnelli, S
    Montagnani, A
    Cepollaro, C
    Franci, M
    Lucani, B
    Gaggiotti, E
    Nuti, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S395 - S395
  • [44] Receptor activator of NF-kB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro
    Yamaguchi, M
    Uchiyama, S
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2004, 14 (01) : 81 - 85
  • [45] Denosumab is a selective inhibitor of human receptor activator of NF-kB ligand that blocks osteoclast formation in vitro and in vivo
    Elliott, R.
    Kostenuik, P.
    Chen, C.
    Kelley, M.
    Hawkins, N.
    Housman, J.
    McCabe, S.
    Mukku, V.
    Sullivan, J.
    Dougall, W.
    EJC SUPPLEMENTS, 2006, 4 (12): : 62 - 62
  • [46] The NF-KB pathway and endocrine therapy resistance in breast cancer
    Khongthong, Phungern
    Roseweir, Antonia K.
    Edwards, Joanne
    ENDOCRINE-RELATED CANCER, 2019, 26 (06) : R369 - R380
  • [47] Denosumab is a selective inhibitor of human receptor activator of NF-Kb ligand (RANKL) that blocks osteoclast formation and function
    Elliott, R.
    Kostenuik, P.
    Chen, C.
    Kelley, M.
    Hawkins, N.
    Housman, J.
    McCabe, S.
    Mukku, V.
    Sullivan, J. K.
    Dougall, W.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S54 - S54
  • [48] Soy protein and n-3 fatty acids prevent receptor activator of NF-kB ligand (RANKL) expression and osteoporosis in ovariectomized mice
    Fernandes, G
    Sun, DX
    Krishnan, A
    Zaman, K
    Lawrence, R
    FASEB JOURNAL, 2002, 16 (04): : A625 - A625
  • [49] High Nuclear Expression of Activated NF-kB is Associated With Increased Recurrence in Breast Cancer Patients
    Bennett, L.
    Mohammed, Z.
    Orange, C.
    Horgan, P.
    Doughty, J.
    Mallon, E.
    Edwards, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S183 - S184
  • [50] Regulation of IKKe expression by androgen receptor and NF-kB transcriptional factor in prostate cancer.
    Péant, B.
    Diallo, J.
    Lessard, L.
    Mes-Masson, A.
    Saad, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 566S - 566S
12345